On January 17, ASE joined a coalition of cardiovascular groups in a comment letter to CMS applauding their proposed decision to enlist Medicare coverage of transcatheter tricuspid value replacements (TTVR) under coverage with evidence development (CED). The comments acknowledge the novel approach CMS is taking that requires the trial sponsor to lead the delivery of a breakthrough device. The societies offer recommendations on best practices to carry out CMS’ goals outlined in the proposed decision.
Publishing date
January 17, 2025
Related Resources
Advocacy
ASE Joins Coalition Supporting Robust NIH Funding and Oversight of Federal Research Barriers
On June 16, ASE joined a broad coalition...
Advocacy
ASE Joins Coalition Requesting a Fix for the Efficiency Adjustment to be Added to Physician Payment Reform
On June 15, ASE joined twenty undersigned organizations...
Advocacy
ASE Joins Comments on the CMS/ONC Interoperability Standards and Prior Authorization for Drugs Proposed Rule
On June 15, ASE joined the Alliance of...